Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies

Esther J Witsch1, Georg Mahlknecht, Jean Wakim

  • 1Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.

Insights

Novel peptide mimotopes targeting the erbb-2 gene receptor were developed. Cyclic versions of these mimotopes effectively inhibit antibody binding to cancer cells, showing potential for erbb-2 cancer vaccines.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • The erbb-2 gene receptor is over-expressed in human cancers, correlating with poor prognosis.
  • Antibody-based therapies targeting erbb-2 are effective in inhibiting cancer progression.
  • Monoclonal antibodies L-26 and N-12 have demonstrated tumor inhibition in preclinical models.

Purpose of the Study:

  • To identify and characterize novel peptide mimotopes of erbb-2 gene protein epitopes.
  • To evaluate the efficacy of these mimotopes in inhibiting antibody binding to erbb-2 expressing cancer cells.
  • To explore the potential of these mimotopes as a basis for cancer vaccine development.

Main Methods:

  • Selection of peptide mimotopes from a constrained random 12-mer peptide phage library specific for antibodies L-26 and N-12.
  • Computational analysis to predict epitopes on the erbb-2 extracellular domain.
  • In vitro assays to assess specificity, binding inhibition, and competition with recombinant erbb-2 protein.
  • Vaccination studies in mice using KLH-coupled cyclic and linear peptides.

Main Results:

  • Peptide mimotopes showed specificity for their respective antibodies (L-26 and N-12) without sequence homology to erbb-2.
  • Cyclic peptide mimotopes, but not linear ones, inhibited antibody binding to erbb-2 expressing cancer cells in a dose-dependent manner.
  • Cyclic peptides competed with erbb-2 protein for antibody binding and elicited specific anti-erbb-2 antibodies upon vaccination.

Conclusions:

  • Novel cyclic peptide mimotopes targeting erbb-2 were identified.
  • These cyclic mimotopes can block antibody-erbb-2 interactions and induce an immune response.
  • The identified peptides represent a promising starting point for developing a vaccine against erbb-2 over-expressing cancers.